We are live on ! Find out more
PRLD icon

Prelude Therapeutics
PRLD

60 hedge funds and large institutions have $188M invested in Prelude Therapeutics in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 24 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

31% more capital invested

Capital invested by funds: $144M → $188M (+$44.2M)

13% more funds holding

Funds holding: 53 → 60 (+7)

1.81% less ownership

Funds ownership: 87.35% → 85.54% (-1.8%)

46% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 24

Holders
60
Holders Change
+7
Holders Change %
+13.21%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
13
Reduced
24
Closed
5
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
-$1.52M

Top Buyers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
+$549K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$511K
3
CS
Candriam SCA
Luxembourg
+$348K
4
Citigroup
Citigroup
New York
+$330K
5
6CM
683 Capital Management
New York
+$183K

Top Sellers

Rank Fund Capital Flow
1
HA
HHLR Advisors
Cayman Islands
-$3.86M
2
Morgan Stanley
Morgan Stanley
New York
-$563K
3
UBS AM
UBS AM
Illinois
-$427K
4
BlackRock
BlackRock
New York
-$420K
5
Two Sigma Investments
Two Sigma Investments
New York
-$344K
Name Holding Trade Value Shares
Change 		Change in
Stake
State Street
26
State Street
Massachusetts
$265K – – –
BCM
27
Bridgeway Capital Management
Texas
$223K – – –
Manulife (Manufacturers Life Insurance)
28
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$191K +$199 +31 +0.1%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$174K -$1.92K -300 -1%
6CM
30
683 Capital Management
New York
$173K +$183K +28,631 New
TD Asset Management
31
TD Asset Management
Ontario, Canada
$172K – – –
BFG
32
Bleakley Financial Group
New Jersey
$135K +$143K +22,325 New
Northern Trust
33
Northern Trust
Illinois
$128K – – –
Man Group
34
Man Group
United Kingdom
$127K +$135K +20,994 New
Citadel Advisors
35
Citadel Advisors
Florida
$110K +$16K +2,498 +16%
BFM
36
Boothbay Fund Management
New York
$106K +$113K +17,623 New
Jane Street
37
Jane Street
New York
$102K +$108K +16,807 New
MFS
38
Mirabella Financial Services
United Kingdom
$97K +$103K +16,058 New
Goldman Sachs
39
Goldman Sachs
New York
$95.2K -$38.3K -5,971 -27%
Commonwealth Equity Services
40
Commonwealth Equity Services
Massachusetts
$92K -$3.59K -560 -4%
Qube Research & Technologies (QRT)
41
Qube Research & Technologies (QRT)
United Kingdom
$79.3K +$84.1K +13,127 New
DA
42
Denali Advisors
California
$49.5K – – –
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
$26K +$634 +99 +2%
Nisa Investment Advisors
44
Nisa Investment Advisors
Missouri
$24K – – –
TRCT
45
Tower Research Capital (TRC)
New York
$21K +$14.6K +2,278 +182%
DFCM
46
Dark Forest Capital Management
Puerto Rico
$18.7K +$19.8K +3,092 New
Rockefeller Capital Management
47
Rockefeller Capital Management
New York
$15K +$16.1K +2,512 New
CG
48
Cutler Group
California
$12K +$13.6K +2,130 New
JP Morgan Chase
49
JP Morgan Chase
New York
$8K -$7.39K -1,154 -47%
UBS Group
50
UBS Group
Switzerland
$6.26K +$6.21K +969 +1,425%
1
2
3

PRLD Hedge Fund Activity: Q4 2022 in Review

60 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q4 2022, worth a combined $188M — up 31% from $144M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new PRLD positions and 5 closed out — a net gain of 7 holders — while 13 added to existing stakes and 24 trimmed.

The largest buyer was Barclays, adding an estimated $549K. The largest seller was HHLR Advisors, exiting entirely with an estimated $3.86M sold.

  • 60 institutional investors held Prelude Therapeutics (PRLD) as of Q4 2022, up from 53 in Q3 2022.
  • Funds reported $188M of Prelude Therapeutics stock for Q4 2022, up 31% quarter-over-quarter.
  • 12 funds opened new Prelude Therapeutics positions in Q4 2022 and 5 closed out, a net change of +7 holders.
  • The largest Prelude Therapeutics buyer in Q4 2022 was Barclays, an estimated $549K added.
  • The largest Prelude Therapeutics seller in Q4 2022 was HHLR Advisors, an estimated $3.86M sold.

Based on aggregated 13F filings for Q4 2022.